Deviant immune responses to allogeneic tumors injected intracamerally and subcutaneously in mice

J. Niederkorn, J. W. Streilein, J. A. Shadduk

Research output: Contribution to journalArticle

137 Citations (Scopus)

Abstract

The ability to introduce carefully controlled numbers of viable cells into the anterior chamber of mouse eyes made it possible to examine the interrelationship between presentation of antigens intracamerally and into conventional body sites and their synergistic/antagonistic effects on the immune system. P815 mastocytoma (DBA/2; H-2(d)) cells are synergic with BALB/c hosts at the major histocompatibility complex but differ at numerous minor histocompatibility loci. When these cells are injected intracamerally into BALB/c mice, they subvert the host's immune response; that is, tumor cells injected subcutaneously developed into tumors. The dynamics of this anterior chamber-associated immune deviation was manipulable. When subcutaneous (SC) inoculations preceded intracameral (IC) inoculations by 5 days or more, systemic anti-DBA/2 immunity elicited by SC inoculation prevented successful engraftment of P815 tumors in the anterior chamber. As the time interval between SC and IC inoculations of P815 cells decreased, the balance between destruction or survival of intraocular tumors was tipped in favour of tumor growth. Intraocular tumor growth increased when IC inoculations preceded SC inoculation and was most impressive when this interval was 7 days. In these mice the tumors grew briskly and aggressively in a fashion comparable to that seen in hosts not receiving prior SC inoculations. The apparent capacity of the immune system to prevent or enhance the growth of tumors can be successfully manipulated inways that suggest the possibility of therapeutic benefit in ophthalmologic disease.

Original languageEnglish (US)
Pages (from-to)355-363
Number of pages9
JournalInvestigative Ophthalmology and Visual Science
Volume20
Issue number3
StatePublished - 1981

Fingerprint

Neoplasms
Anterior Chamber
Minor Histocompatibility Loci
Immune System
Growth
Mastocytoma
Antigen Presentation
Major Histocompatibility Complex
Immunity
Cell Count
Therapeutics

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Deviant immune responses to allogeneic tumors injected intracamerally and subcutaneously in mice. / Niederkorn, J.; Streilein, J. W.; Shadduk, J. A.

In: Investigative Ophthalmology and Visual Science, Vol. 20, No. 3, 1981, p. 355-363.

Research output: Contribution to journalArticle

@article{5ec5ad9cb2f54641bacec5e7c55bb26a,
title = "Deviant immune responses to allogeneic tumors injected intracamerally and subcutaneously in mice",
abstract = "The ability to introduce carefully controlled numbers of viable cells into the anterior chamber of mouse eyes made it possible to examine the interrelationship between presentation of antigens intracamerally and into conventional body sites and their synergistic/antagonistic effects on the immune system. P815 mastocytoma (DBA/2; H-2(d)) cells are synergic with BALB/c hosts at the major histocompatibility complex but differ at numerous minor histocompatibility loci. When these cells are injected intracamerally into BALB/c mice, they subvert the host's immune response; that is, tumor cells injected subcutaneously developed into tumors. The dynamics of this anterior chamber-associated immune deviation was manipulable. When subcutaneous (SC) inoculations preceded intracameral (IC) inoculations by 5 days or more, systemic anti-DBA/2 immunity elicited by SC inoculation prevented successful engraftment of P815 tumors in the anterior chamber. As the time interval between SC and IC inoculations of P815 cells decreased, the balance between destruction or survival of intraocular tumors was tipped in favour of tumor growth. Intraocular tumor growth increased when IC inoculations preceded SC inoculation and was most impressive when this interval was 7 days. In these mice the tumors grew briskly and aggressively in a fashion comparable to that seen in hosts not receiving prior SC inoculations. The apparent capacity of the immune system to prevent or enhance the growth of tumors can be successfully manipulated inways that suggest the possibility of therapeutic benefit in ophthalmologic disease.",
author = "J. Niederkorn and Streilein, {J. W.} and Shadduk, {J. A.}",
year = "1981",
language = "English (US)",
volume = "20",
pages = "355--363",
journal = "Investigative Ophthalmology and Visual Science",
issn = "0146-0404",
publisher = "Association for Research in Vision and Ophthalmology Inc.",
number = "3",

}

TY - JOUR

T1 - Deviant immune responses to allogeneic tumors injected intracamerally and subcutaneously in mice

AU - Niederkorn, J.

AU - Streilein, J. W.

AU - Shadduk, J. A.

PY - 1981

Y1 - 1981

N2 - The ability to introduce carefully controlled numbers of viable cells into the anterior chamber of mouse eyes made it possible to examine the interrelationship between presentation of antigens intracamerally and into conventional body sites and their synergistic/antagonistic effects on the immune system. P815 mastocytoma (DBA/2; H-2(d)) cells are synergic with BALB/c hosts at the major histocompatibility complex but differ at numerous minor histocompatibility loci. When these cells are injected intracamerally into BALB/c mice, they subvert the host's immune response; that is, tumor cells injected subcutaneously developed into tumors. The dynamics of this anterior chamber-associated immune deviation was manipulable. When subcutaneous (SC) inoculations preceded intracameral (IC) inoculations by 5 days or more, systemic anti-DBA/2 immunity elicited by SC inoculation prevented successful engraftment of P815 tumors in the anterior chamber. As the time interval between SC and IC inoculations of P815 cells decreased, the balance between destruction or survival of intraocular tumors was tipped in favour of tumor growth. Intraocular tumor growth increased when IC inoculations preceded SC inoculation and was most impressive when this interval was 7 days. In these mice the tumors grew briskly and aggressively in a fashion comparable to that seen in hosts not receiving prior SC inoculations. The apparent capacity of the immune system to prevent or enhance the growth of tumors can be successfully manipulated inways that suggest the possibility of therapeutic benefit in ophthalmologic disease.

AB - The ability to introduce carefully controlled numbers of viable cells into the anterior chamber of mouse eyes made it possible to examine the interrelationship between presentation of antigens intracamerally and into conventional body sites and their synergistic/antagonistic effects on the immune system. P815 mastocytoma (DBA/2; H-2(d)) cells are synergic with BALB/c hosts at the major histocompatibility complex but differ at numerous minor histocompatibility loci. When these cells are injected intracamerally into BALB/c mice, they subvert the host's immune response; that is, tumor cells injected subcutaneously developed into tumors. The dynamics of this anterior chamber-associated immune deviation was manipulable. When subcutaneous (SC) inoculations preceded intracameral (IC) inoculations by 5 days or more, systemic anti-DBA/2 immunity elicited by SC inoculation prevented successful engraftment of P815 tumors in the anterior chamber. As the time interval between SC and IC inoculations of P815 cells decreased, the balance between destruction or survival of intraocular tumors was tipped in favour of tumor growth. Intraocular tumor growth increased when IC inoculations preceded SC inoculation and was most impressive when this interval was 7 days. In these mice the tumors grew briskly and aggressively in a fashion comparable to that seen in hosts not receiving prior SC inoculations. The apparent capacity of the immune system to prevent or enhance the growth of tumors can be successfully manipulated inways that suggest the possibility of therapeutic benefit in ophthalmologic disease.

UR - http://www.scopus.com/inward/record.url?scp=0019413126&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019413126&partnerID=8YFLogxK

M3 - Article

C2 - 6782034

AN - SCOPUS:0019413126

VL - 20

SP - 355

EP - 363

JO - Investigative Ophthalmology and Visual Science

JF - Investigative Ophthalmology and Visual Science

SN - 0146-0404

IS - 3

ER -